Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase NA 1

Status

Completed 45Active not recruiting 9Recruiting 8Terminated 7Withdrawn 4Unknown 3Not yet recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 28Leukemia, Myeloid, Acute 27Neoplasms 26Recurrence 22Neoplasm Metastasis 22Multiple Myeloma 20Advanced Solid Tumors 20Lymphoma, B-Cell 19Breast Neoplasms 17Pancreatic Neoplasms 14Lung Neoplasms 13Glioblastoma 13Carcinoma, Hepatocellular 13Brain Neoplasms 13Lymphoma 12Glioma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Melanoma 11Hematologic Neoplasms 11Triple Negative Breast Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Ovarian Neoplasms 10Leukemia 10Advanced Solid Tumor 10Prostatic Neoplasms 9Head and Neck Neoplasms 9Lymphoma, Non-Hodgkin 8Esophageal Neoplasms 8Sarcoma 7

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Ependymoma × Clear all
NCT07390539 2026-02-05

B7-H3.CD28Z.CART in CNS Neoplasms

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
70 enrolled
CNS

Brain Neoplasms, Ependymoma, Medulloblastoma, Meningeal Neoplasms, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07061626 2025-07-11

Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma

Plus Therapeutics

Phase 1 Not yet recruiting
56 enrolled

Ependymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡